Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Guggenheim raises CG Oncology stock price target on trial results

Guggenheim raises CG Oncology stock price target on trial results

Guggenheim raised its price target on MSG Rangers stock to $299 from $278 on Tuesday, maintaining a Buy rating. The company's stock is currently trading at $247.84, having surged 7.7% over the past week and nearing its 52-week high of $255. Guggenheim's updated model was based on the company's fiscal 2027 first-quarter earnings.

Despite not hosting an earnings call due to the timing of the quarter, Guggenheim believes the Rangers have a significant discount between its net asset value and intrinsic value. Valuations from Sportico and Forbes were cited at $3.65 billion and $4.0 billion, respectively, while the Rangers' market cap is just $2.99 billion. The stock trades near its 52-week high with an EXCELLENT financial health score, and BTIG has adjusted its price target to $313, citing a valuation gap and increased investor interest following the Rangers' spin-off from Madison Square Garden Knickerbockers.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Other reports of this story

Every outlet that reported this, and when →

Read the original at investing.com →